Publications
5600 Results
- Journal / Conference
- Clinical Cancer Research Jan 5;30(1):33-38
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID37882676
- PMC
- PMC10842092
- Study Number(s)
- S1609
A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2200
PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2210
SWOG S2210: A PHASE II STUDY OF NEOADJUVANT CARBOPLATIN FOR LOCALIZED, HIGH RISK PROSTATE CANCER WITH GERMLINE BRCA1/2 MUTATIONS
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral; J Clin Oncol 42, 2024 (suppl 4; abstr LBA531)
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A031501
AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIBC) vs Observation
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient level analysis of SWOG 1216 trial
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1605
Urinary comprehensive genomic profile correlates with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605
- Journal / Conference
- Cancer May 15;130(10):1784-1796
- Year
- 2024
- Research Committee(s)
- Melanoma
- PMID
- PMID38261444
- Study Number(s)
- S1221
A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers
- Journal / Conference
- Clinical Cancer Research Apr 15;30(8):1655-1668
- Year
- 2024
- Research Committee(s)
- Lung
- PMID
- PMID38277235
- PMC
- PMC11016892
- Study Number(s)
- S1400I
Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- Leukemia Feb;38(2):389-392
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38263433